The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1987-1990, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-922237
ABSTRACT
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease. HCV is not only related to hepatic malignancies but may also promote lymphoid neoplasms. Currently, research has confirmed HCV-related lymphoma, including marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma (BL). Many types of research have shown that antiviral therapy can improve or even remission several HCV-related lymphomas. The direct-acting antiviral agents (DAAs) (such as NS5A protease inhibitors, NS4/4A protease inhibitors and viral polymerase inhibitors) have shown clinical advantages of high efficacy and low side effects for both virus elimination and tumor regression in several HCV-related lymphomas, which may make the selected HCV-related lymphoma patients treated without chemotherapy. In this review the research progress and development direction of antiviral therapy in treating HCV-related lymphoma has summarized briefly.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Linfoma de Células B Grandes Difuso
/
Hepatitis C
/
Hepacivirus
/
Linfoma de Células B de la Zona Marginal
/
Hepatitis C Crónica
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS